# What's Next for IVF
In vitro fertilization has transformed from a singular medical miracle into routine reproductive medicine. Louise Joy Brown's birth in 1976 opened a path that now produces roughly 2 percent of all births globally. Yet the field remains ripe for disruption.
Current IVF faces persistent challenges: success rates plateau around 40 to 50 percent per cycle for patients under 35, costs exceed $15,000 per attempt in the US, and the process demands significant time and emotional investment. Several emerging technologies promise to change this calculus.
Artificial gametes, developed in labs rather than harvested from patients, could eliminate age-related fertility decline. Researchers at Cambridge and elsewhere have already created rudimentary eggs and sperm from stem cells. This approach sidesteps the biological clock entirely, allowing older patients viable reproductive options.
Non-invasive embryo monitoring represents another frontier. Current methods require biopsies that potentially harm developing embryos. New optical imaging techniques and AI-powered analysis could assess embryo health without physical intervention, improving selection accuracy and reducing failed transfers.
Genetic screening has become standard, but next-generation approaches promise more precision. Polygenic risk scoring could identify embryos with lower disease susceptibility, though this raises thorny ethical questions about enhancement versus therapy.
Automation and miniaturization are shrinking both cost and complexity. Microfluidic devices could enable "lab-on-a-chip" IVF procedures, decentralizing fertility treatment from specialized clinics to standard medical facilities. This shift could dramatically reduce expenses and expand access in resource-limited regions.
The timeline remains uncertain. Artificial gametes likely need five to ten years before human trials. Improved imaging could see adoption within two to three years. The regulatory environment also matters enormously. Countries like Japan have embraced faster approval pathways for reproductive technologies,